Wisevoter
U.S.

GE HealthCare Acquired SOFIE Biosciences for $945 Million

The medical technology giant entered a definitive agreement to purchase the radiopharmaceutical firm.

Updated on Oct. 5, 2026 in Healthcare

Isometric editorial illustration of a medical diagnostic scanner assembly, rendered in clean geometric volumes with a muted palette.
GE HealthCare has agreed to acquire radiopharmaceutical firm SOFIE Biosciences for $945 million to expand its diagnostic capabilities in the United States. AI Illustration. Upload story photo >

Live Poll

Does company consolidation in the medical industry generally lead to better patient access to care?

GE HealthCare has agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. The move is designed to expand the company's footprint within the U.S. PET radiopharmaceutical supply chain.

Why it matters

The acquisition positions GE HealthCare to participate in high-growth radiopharmaceutical markets. By integrating SOFIE Biosciences, the company aims to scale its diagnostic capabilities in the United States.

The deal involves 15 contract manufacturing organization sites and 21 operating cyclotrons currently held by SOFIE Biosciences. GE HealthCare, which employs 54,000 colleagues, supported 140 million medical procedures with its imaging agents in 2025.

The players

GE HealthCare

This global medical technology firm provides healthcare solutions and diagnostic agents for medical imaging and monitoring.

SOFIE Biosciences

This company specializes in the development and manufacturing of radiopharmaceuticals for PET imaging applications.

Trilantic North America

This private equity firm is the current owner of SOFIE Biosciences.

The details

SOFIE Biosciences will join GE HealthCare's Pharmaceutical Diagnostics segment upon the completion of the transaction. The agreement is projected to be accretive to revenue growth and earnings in the first full year of ownership.

Timeline

  1. In 2025, GE HealthCare imaging agents supported 140 million procedures.

  2. The acquisition agreement was announced on October 5, 2026.

  3. The transaction is expected to close in the first half of 2027.

Market Landscape

This move represents a significant consolidation within the diagnostic imaging market as major firms seek to secure their own production networks. GE HealthCare is positioning itself to compete more aggressively against rivals by bringing decentralized radiopharmaceutical manufacturing in-house.

Average patients may see improved access to specialized PET diagnostic procedures as supply chain reliability increases. There are no immediate changes expected to consumer pricing or service availability for individual patients.

The takeaway

Large-scale acquisitions in the diagnostic sector illustrate the increasing importance of integrated supply chains for high-tech medical treatments. These corporate moves are designed to ensure that critical diagnostic materials remain available as clinical demand continues to grow.

Further reading

For more context on how clinical supply chains are changing, visit the Healthcare section.

Live Poll

Does company consolidation in the medical industry generally lead to better patient access to care?